Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

Bausch + Lomb Names Daniel M. Wechsler as Global President, Pharmaceuticals


FOR RELEASE 6/21/2010, Monday


ROCHESTER, NY--(Marketwire - September 9, 2010) -  Bausch + Lomb, the global eye health company, has named Daniel M. Wechsler as corporate vice president and global president of its Pharmaceuticals business.

"Dan has a strong track record as a senior executive driving high performance in global health care companies," said Brent Saunders, chief executive officer, Bausch + Lomb. "His recruitment reflects our continuing progress toward transforming B+L into a high-performance competitor."

Mr. Wechsler was most recently head of U.S. Strategy, Commercial Model Innovation and Business Development for Merck & Co., a role to which he was appointed following the company's acquisition of Schering-Plough Corporation in 2009.

From 2005 to 2009, he was group vice president, Global Business Operations and Selling Excellence, for Schering-Plough, and a member of the global management team. As part of this multifaceted position, Mr. Wechsler led the human health business integration following the company's acquisition of Organon, with resulting cost savings and sales growth.

In 2003, Mr. Wechsler joined Pfizer Inc. as vice president for its multibillion-dollar U.S. Specialty Sales organization, with responsibility for the oncology, ophthalmics, medical/surgical, Agouron, cardiovascular, urology and gynecology, endocrine care and women's health franchises. His leadership drove consistent double-digit sales increases.

He began his career in 1991 with The Upjohn Company (later Pharmacia Corporation), holding a variety of positions with increasing responsibilities for sales and sales training. His tenure there culminated in his role as vice president, Sales, Institutional Division, where he led the company's U.S. institutional, federal government, and clinical education manager division.

Mr. Wechsler earned his master's degree from the University of Rochester and holds a bachelor's degree from the State University of New York at Brockport. He will be based at the company's primary Pharmaceuticals business site in Madison, N.J.

Mr. Wechsler assumes Pharmaceuticals responsibility from Mr. Saunders, who has been acting as interim global president of the business unit for the past several months.

Bausch + Lomb is dedicated to bringing visionary ideas to eye health. It is a global leader in contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. Its pharmaceuticals portfolio includes prescription and over-the-counter products designed to treat a wide range of conditions including infection, inflammation, and allergy, as well as eye nutrition.

About Bausch + Lomb
Bausch + Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch + Lomb name is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at


Actions: E-mail | Permalink |